(NASDAQ: GRI) Gri Bio's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 135.17%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 102.53%.
Gri Bio's earnings in 2026 is -$11,956,000.On average, 3 Wall Street analysts forecast GRI's earnings for 2026 to be -$2,546,864, with the lowest GRI earnings forecast at -$3,823,547, and the highest GRI earnings forecast at -$1,198,652. On average, 2 Wall Street analysts forecast GRI's earnings for 2027 to be -$642,171, with the lowest GRI earnings forecast at -$623,097, and the highest GRI earnings forecast at -$667,603.
In 2028, GRI is forecast to generate -$525,413 in earnings, with the lowest earnings forecast at -$509,806 and the highest earnings forecast at -$546,221.